Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies

Cancer Treatment Reviews

Volumn 39, Issue 6, 2013, Pages 632-639

  Okroj, Marcin ^a   Österborg, Anders ^b   Blom, Anna M ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies; CD20; CLL; Immunotherapy; Lymphoma

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; FBTA 05; FLUDARABINE; IBRITUMOMAB TIUXETAN; LFBR 603; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OCARATUZUMAB; OCRELIZUMAB; OFATUMUMAB; PRO 131921; RETUXIRA; RITUXIMAB; TOSITUMOMAB; TRU 015; UNCLASSIFIED DRUG; VELTUZUMAB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; COMPLEMENT SYSTEM; CYTOLYSIS; DRUG BINDING; DRUG EFFICACY; HUMAN; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 84878919900     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.10.008     Document Type: Review

References (96)

1. Friec G.L., Kemper C. Complement: coming full circle. Arch Immunol Ther Exp (Warsz) 2009, 57:393-407.
2. Chandrasekaran E.V., Xue J., Neelamegham S., Matta K.L. The pattern of glycosyl- and sulfotransferase activities in cancer cell lines: a predictor of individual cancer-associated distinct carbohydrate structures for the structural identification of signature glycans. Carbohydr Res 2006, 341:983-994.
3. Galeotti T., Borrello S., Minotti G., Masotti L. Membrane alterations in cancer cells: the role of oxy radicals. Ann N Y Acad Sci 1986, 488:468-480.
4. Cejas P., Casado E., Belda-Iniesta C., De Castro J., Espinosa E., Redondo A., et al. Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control 2004, 15:707-719.
5. Paschen A., Eichmuller S., Schadendorf D. Identification of tumor antigens and T-cell epitopes, and its clinical application. Cancer Immunol Immunother 2004, 53:196-203.
6. Budzko D.B., Lachmann P.J., McConnell I. Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol 1976, 22:98-109.
7. Fujita T., Taira S., Kodama N., Matsushita M., Fujita T. Mannose-binding protein recognizes glioma cells: in vitro analysis of complement activation on glioma cells via the lectin pathway. Jpn J Cancer Res 1995, 86:187-192.
8. Ytting H., Jensenius J.C., Christensen I.J., Thiel S., Nielsen H.J. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand J Gastroenterol 2004, 39:674-679.
9. Fust G., Czink E., Minh D., Miszlay Z., Varga L., Hollan S.R. Depressed classical complement pathway activities in chronic lymphocytic leukaemia. Clin Exp Immunol 1985, 60:489-495.
10. Irie K., Irie R.F., Morton D.L. Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science 1974, 186:454-456.
11. Jurianz K., Ziegler S., Garcia-Schuler H., Kraus S., Bohana-Kashtan O., Fishelson Z., et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999, 36:929-939.
12. Fishelson Z., Donin N., Zell S., Schultz S., Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003, 40:109-123.
13. Kumar S., Vinci J.M., Pytel B.A., Baglioni C. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res 1993, 53:348-353.
14. Okroj M., Hsu Y.F., Ajona D., Pio R., Blom A.M. Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 2008, 45:169-179.
15. Junnikkala S., Jokiranta T.S., Friese M.A., Jarva H., Zipfel P.F., Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000, 164:6075-6081.
16. Donin N., Jurianz K., Ziporen L., Schultz S., Kirschfink M., Fishelson Z. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol 2003, 131:254-263.
17. Jurianz K., Ziegler S., Donin N., Reiter Y., Fishelson Z., Kirschfink M. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int J Cancer 2001, 93:848-854.
18. Spiller O.B., Robinson M., O'Donnell E., Milligan S., Morgan B.P., Davison A.J., et al. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol 2003, 77:592-599.
19. Mark L., Spiller O.B., Villoutreix B.O., Blom A.M. Kaposi's sarcoma-associated herpes virus complement control protein: KCP - complement inhibition and more. Mol Immunol 2007, 44:11-22.
20. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008, 9:1225-1235.
21. Sikkeland L.I., Thorgersen E.B., Haug T., Mollnes T.E. Complement activation and cytokine response by BioProtein, a bacterial single cell protein. Clin Exp Immunol 2007, 148:146-152.
22. Okroj M., Corrales L., Stokowska A., Pio R., Blom A.M. Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol Immunother 2009, 58:1771-1880.
23. Collard C.D., Vakeva A., Bukusoglu C., Zund G., Sperati C.J., Colgan S.P., et al. Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Circulation 1997, 96:326-333.
24. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
25. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
26. Gelderman K.A., Lam S., Gorter A. Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs. Expert Opin Biol Ther 2005, 5:1593-1601.
27. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007, 44:3823-3837.
28. Beers S.A., French R.R., Chan H.T., Lim S.H., Jarrett T.C., Vidal R.M., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010, 115:5191-5201.
29. Winiarska M., Glodkowska-Mrowka E., Bil J., Golab J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci 2010, 16:277-306.
30. Uchida J., Lee Y., Hasegawa M., Liang Y., Bradney A., Oliver J.A., et al. Mouse CD20 expression and function. Int Immunol 2004, 16:119-129.
31. O'Keefe T.L., Williams G.T., Davies S.L., Neuberger M.S. Mice carrying a CD20 gene disruption. Immunogenetics 1998, 48:125-132.
32. Tedder T.F., Forsgren A., Boyd A.W., Nadler L.M., Schlossman S.F. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 1986, 16:881-887.
33. Kuijpers T.W., Bende R.J., Baars P.A., Grummels A., Derks I.A., Dolman K.M., et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010, 120:214-222.
34. Teeling J.L., Mackus W.J., Wiegman L.J., van den Brakel J.H., Beers S.A., French R.R., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006, 177:362-371.
35. van Meerten T., Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol 2010, 47:199-210.
36. Ivanov A., Beers S.A., Walshe C.A., Honeychurch J., Alduaij W., Cox K.L., et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009, 119:2143-2159.
37. Honeychurch J., Alduaij W., Azizyan M., Cheadle E.J., Pelicano H., Ivanov A., et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012, 119:3523-3533.
38. Murawski N., Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 2010, 11:1074-1085.
39. Wang S.Y., Racila E., Taylor R.P., Weiner G.J. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 2008, 111:1456-1463.
40. Wang S.Y., Veeramani S., Racila E., Cagley J., Fritzinger D.C., Vogel C.W., et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009, 114:5322-5330.
41. van Meerten T., van Rijn R.S., Hol S., Hagenbeek A., Ebeling S.B. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006, 12:4027-4035.
42. Mishima Y., Terui Y., Mishima Y., Kuniyoshi R., Matsusaka S., Mikuniya M., et al. High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRIIIa polymorphism. Int Immunol 2012, 24:477-483.
43. Alduaij W., Illidge T.M. The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood 2011, 117:2993-3001.
44. Lim S.H., Beers S.A., French R.R., Johnson P.W., Glennie M.J., Cragg M.S. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010, 95:135-143.
45. Robak T., Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011, 25:13-25.
46. Ge X., Wu L., Hu W., Fernandes S., Wang C., Li X., et al. RILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia. Clin Cancer Res 2011, 17:6702-6711.
47. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-1800.
48. Pawluczkowycz A.W., Beurskens F.J., Beum P.V., Lindorfer M.A., van de Winkel J.G., Parren P.W., et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009, 183:749-758.
49. Bluemel C., Hausmann S., Fluhr P., Sriskandarajah M., Stallcup W.B., Baeuerle P.A., et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010, 59:1197-1209.
50. Xia M.Q., Hale G., Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993, 30:1089-1096.
51. Ragupathi G., Liu N.X., Musselli C., Powell S., Lloyd K., Livingston P.O. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 2005, 174:5706-5712.
52. Cragg M.S., Morgan S.M., Chan H.T., Morgan B.P., Filatov A.V., Johnson P.W., et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003, 101:1045-1052.
53. O'Brien S., Osterborg A. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2010, 10:361-368.
54. Czuczman M.S., Fayad L., Delwail V., Cartron G., Jacobsen E., Kuliczkowski K., et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012, 119:3698-3704.
55. Wierda W.G., Padmanabhan S., Chan G.W., Gupta I.V., Lisby S., Osterborg A. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011, 118:5126-5129.
56. Morschhauser F., Marlton P., Vitolo U., Linden O., Seymour J.F., Crump M., et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010, 21:1870-1876.
57. Bowles J.A., Wang S.Y., Link B.K., Allan B., Beuerlein G., Campbell M.A., et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006, 108:2648-2654.
58. Goldenberg D.M., Rossi E.A., Stein R., Cardillo T.M., Czuczman M.S., Hernandez-Ilizaliturri F.J., et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009, 113:1062-1070.
59. Carnahan J., Stein R., Qu Z., Hess K., Cesano A., Hansen H.J., et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007, 44:1331-1341.
60. Miwa T., Song W.C. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol 2001, 1:445-459.
61. Blom A.M., Villoutreix B.O., Dahlback B. Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?. Mol Immunol 2004, 40:1333-1346.
62. Ong G.L., Mattes M.J. Mouse strains with typical mammalian levels of complement activity. J Immunol Methods 1989, 125:147-158.
63. Ebanks R.O., Isenman D.E. Mouse complement component C4 is devoid of classical pathway C5 convertase subunit activity. Mol Immunol 1996, 33:297-309.
64. Cragg M.S., Glennie M.J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004, 103:2738-2743.
65. Barth M.J., Hernandez-Ilizaliturri F.J., Mavis C., Tsai P.C., Gibbs J.F., Deeb G., et al. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol 2012, 156:490-498.
66. de Haij S., Jansen J.H., Boross P., Beurskens F.J., Bakema J.E., Bos D.L., et al. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res 2010, 70:3209-3217.
67. Uchida J., Hamaguchi Y., Oliver J.A., Ravetch J.V., Poe J.C., Haas K.M., et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004, 199:1659-1669.
68. Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003, 171:1581-1587.
69. Boross P., Jansen J.H., de Haij S., Beurskens F.J., van der Poel C.E., Bevaart L., et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica 2011, 96:1822-1830.
70. Imai M., Landen C., Ohta R., Cheung N.K., Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 2005, 65:10562-10568.
71. Golay J., Introna M. Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys 2012, 526:146-153.
72. Harjunpaa A., Junnikkala S., Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000, 51:634-641.
73. Foran J.M., Rohatiner A.Z., Cunningham D., Popescu R.A., Solal-Celigny P., Ghielmini M., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317-324.
74. Weng W.K., Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001, 98:1352-1357.
75. Colombat P., Salles G., Brousse N., Eftekhari P., Soubeyran P., Delwail V., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101-106.
76. Ramos O.F., Sarmay G., Klein E., Yefenof E., Gergely J. Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum. Proc Natl Acad Sci USA 1985, 82:5470-5474.
77. Kennedy A.D., Beum P.V., Solga M.D., DiLillo D.J., Lindorfer M.A., Hess C.E., et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004, 172:3280-3288.
78. Xu W., Miao K.R., Zhu D.X., Fang C., Zhu H.Y., Dong H.J., et al. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer 2011, 128:2192-2201.
79. Klepfish A., Gilles L., Ioannis K., Rachmilewitz E.A., Schattner A. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. Ann N Y Acad Sci 2009, 1173:865-873.
80. Golay J., Lazzari M., Facchinetti V., Bernasconi S., Borleri G., Barbui T., et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001, 98:3383-3389.
81. Middleton O., Cosimo E., Dobbin E., McCaig A.M., Clarke C., Brant A.M., et al. Investigation of the factors that influence complement-dependent cytotoxicity (CDC) following ofatumumab treatment in chronic lymphocytic leukaemia. Immunology 2012, 137(Suppl. 1):196.
82. Koski C.L., Ramm L.E., Hammer C.H., Mayer M.M., Shin M.L. Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci USA 1983, 80:3816-3820.
83. Bohana-Kashtan O., Ziporen L., Donin N., Kraus S., Fishelson Z. Cell signals transduced by complement. Mol Immunol 2004, 41:583-597.
84. Cragg M.S., Howatt W.J., Bloodworth L., Anderson V.A., Morgan B.P., Glennie M.J. Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ 2000, 7:48-58.
85. Mossner E., Brunker P., Moser S., Puntener U., Schmidt C., Herter S., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115:4393-4402.
86. Patz M., Isaeva P., Forcob N., Muller B., Frenzel L.P., Wendtner C.M., et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2010, 152:295-306.
87. Bologna L., Gotti E., Manganini M., Rambaldi A., Intermesoli T., Introna M., et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011, 186:3762-3769.
88. Takada E., Hata K., Mizuguchi J. C-Jun-NH2-terminal kinase potentiates apoptotic cell death in response to carboplatin in B lymphoma cells. Cancer Chemother Pharmacol 2008, 62:569-576.
89. Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947.
90. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
91. Mishima Y., Sugimura N., Matsumoto-Mishima Y., Terui Y., Takeuchi K., Asai S., et al. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin Cancer Res 2009, 15:3624-3632.
92. Beurskens F.J., Lindorfer M.A., Farooqui M., Beum P.V., Engelberts P., Mackus W.J., et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012, 188:3532-3541.
93. Dijoseph J.F., Dougher M.M., Armellino D.C., Kalyandrug L., Kunz A., Boghaert E.R., et al. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol Immunother 2007, 56:1107-1117.
94. Stanglmaier M., Faltin M., Ruf P., Bodenhausen A., Schroder P., Lindhofer H. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 2008, 123:1181-1189.
95. Stolz C., Hess G., Hahnel P.S., Grabellus F., Hoffarth S., Schmid K.W., et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 2008, 112:3312-3321.
96. Pedersen I.M., Buhl A.M., Klausen P., Geisler C.H., Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002, 99:1314-1319.